Your partner in science for end-to-end CRDMO solutions
Target validation is a crucial first step in evaluating the value of intervention in disease. The drug discovery and development process is only initiated on validated targets that impact disease outcomes. In appropriate models, target overexpression, KO KNOCKOUT, KNOCKDOWN studies often support validation. This process, typically spanning 4 to 6 months, is essential for demonstrating the target's value in disease development and its therapeutic potential for intervention. Early and comprehensive target validation establishes a strong connection between target manipulation and disease progression.
Jubilant Biosys has a proven track record in validating disease-modifying targets across various target classes and therapeutic areas.
